Up to 70% of mBC patients have luminal BC, which is defined by estrogen receptor (ER) positive (+) and human epidermal growth factor 2 (HER2) negative (−) expression [5], with a median overall survival (OS) of as long as 57 months [6]. Here, ERBB2 is linked to breast cancer.